<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841059</url>
  </required_header>
  <id_info>
    <org_study_id>HYS-SEX-QOL-POP</org_study_id>
    <nct_id>NCT02841059</nct_id>
  </id_info>
  <brief_title>The Pelvic Floor Function and Sexual Life of the Women After Different Type of Hysterectomy</brief_title>
  <acronym>HYS-PF-QOL</acronym>
  <official_title>The Association of Total Hysterectomy and Disorders of Female Pelvic Floor or Sexual Function: a Survey on Pelvic Floor Function and Sexual Life for Women After Different Type of Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, comparative non-randomized multiple teaching hospitals study, the&#xD;
      investigators try to determine the relationship of total hysterectomy and Taiwanese female&#xD;
      pelvic floor and sexual function from the view of epidemiology and clinical survey. This is&#xD;
      an important issue that related to female autonomy, health care resources and even national&#xD;
      health policy. The study results will help to understand whether there is unnecessary part in&#xD;
      the current hysterectomy procedures and its potential health hazard.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with benign gynecology disease and indicated for laparoscopic hysterectomy&#xD;
      (laparoscopic subtotal hysterectomy: LSH, laparoscopic cervical ligament sparing&#xD;
      hysterectomy: CLSH, laparoscopic assisted vaginal hysterectomy: LAVH) are invited and&#xD;
      explained the details of the protocol by the surgeon. The types of hysterectomy are&#xD;
      determined by the patient and the surgeon together after discussion. All participant have to&#xD;
      sign the informed consent. The participant will be followed up for two years after surgery.&#xD;
      Preoperative evaluation on uterine condition, pelvic floor, questionaires were recorded. The&#xD;
      perioperative parameters including surgical time, blood loss, and postoperative parameters&#xD;
      such as pain score, hospitalization etc were recorded. The postoperative evaluation on pelvic&#xD;
      floor condition, questionaires etc were also recorded at different time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Quality of life change</measure>
    <time_frame>up to 12 months after hysterectomy</time_frame>
    <description>Evaluate the change of quality of life by questionaire --WHOQOL-BREF Taiwan version, at preoperation,1,3,6 and 12 months after hysterectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic organ prolapse change</measure>
    <time_frame>up to 24 months after hysterectomy</time_frame>
    <description>evaluate by Pelvic Organ Prolapse Quantification System (POP-Q) at preoperation, 6,12 and 24 months after hysterectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary disorders change</measure>
    <time_frame>preoperation and 3,6 and 12 months after hysterectomy</time_frame>
    <description>evaluate by UDI-6 short form at preoperation,3,6 and 12 months after hysterectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual life change</measure>
    <time_frame>preoperation and 3,6 and 12 months after hysterectomy</time_frame>
    <description>short form of PISQ-9 approved by International Urogynecological Association, IUGA, at preoperation,3,6 and 12 months after hysterectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence status change</measure>
    <time_frame>preoperation and 3,6 and 12 months after hysterectomy</time_frame>
    <description>evaluate by IIQ-7 short form at preoperation,3,6 and 12 months after hysterectomy.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Quality of Life</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Laparoscopic subtotal hysterectomy</arm_group_label>
    <description>women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic CLSH</arm_group_label>
    <description>women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic AVH</arm_group_label>
    <description>women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LSH</intervention_name>
    <description>laparoscopic subtotal hysterectomy: LSH</description>
    <arm_group_label>Laparoscopic subtotal hysterectomy</arm_group_label>
    <other_name>laparoscopic subtotal hysterectomy: LSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CLSH</intervention_name>
    <description>laparoscopic cervical ligament sparing hysterectomy: CLSH</description>
    <arm_group_label>Laparoscopic CLSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LAVH</intervention_name>
    <description>laparoscopic assisted vaginal hysterectomy: LAVH</description>
    <arm_group_label>Laparoscopic AVH</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who is indicated for hysterectomy due to benign gynecology disease. The&#xD;
        participant's husband is also welcomed to join the survey of the sexual life questionnaire&#xD;
        but this is not a necessary inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient who is indicated for hysterectomy due to benign gynecology disease. The&#xD;
             participant's husband is also welcomed to join the survey of the sexual life&#xD;
             questionnaire but this is not a necessary inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspect of or diagnosed as cancer patient&#xD;
&#xD;
          2. Age &lt; 30 or &gt; 50 years old&#xD;
&#xD;
          3. Menopausal woman or woman who is nulliparous&#xD;
&#xD;
          4. Patient with advanced pelvic floor prolapse (stage 2, 3, 4) including uterine&#xD;
             prolapse, cystocele, enterocele, rectocele.&#xD;
&#xD;
          5. Patient with prominent urinary incontinence that affect social activity or suggested&#xD;
             to have surgery by gynecologist or urologist.&#xD;
&#xD;
          6. Patient with severe medical diseases such as liver cirrhosis, heart failure, poor&#xD;
             control diabetes mellitus etc.&#xD;
&#xD;
          7. Patient with severe pelvic inflammatory disease/tubo-ovarian abcess or pelvic&#xD;
             endometriosis or history of severe pelvic adhesions.&#xD;
&#xD;
          8. Psychiatric patients&#xD;
&#xD;
          9. Patient with chronic lung disease such as bronchial asthma, bronchiectasis, chronic&#xD;
             obstructive pulmonary disease and interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mun-Kun Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dalin Tzu Chi Hospital</name>
      <address>
        <city>Chiayi</city>
        <zip>62224</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mennonite Memorial Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>23142</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>POP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

